Xylem Inc. XYL
| Analyst |
Entreprise |
Price during analysis |
Target price |
Potential gain |
Publication date |
| Damian Karas |
UBS |
127.5 $ |
165 $ |
37.50 % |
13/08/2024 |
| Michael Halloran |
Robert W. Baird |
133.48 $ |
170 $ |
36.52 % |
31/07/2024 |
| Bryan Blair |
Oppenheimer |
139.4 $ |
152 $ |
12.60 % |
31/05/2024 |
| John Eade |
Argus Research |
140.36 $ |
165 $ |
24.64 % |
29/05/2024 |
| Brett Linzey |
Mizuho Securities |
135.99 $ |
135 $ |
-0.99 % |
03/05/2024 |
| Deane Dray |
RBC Capital |
135.99 $ |
162 $ |
26.01 % |
03/05/2024 |
| Michael Halloran |
Robert W. Baird |
135.99 $ |
155 $ |
19.01 % |
03/05/2024 |
| Brad Hewitt |
Wolfe Research |
128.27 $ |
143 $ |
14.73 % |
08/04/2024 |
| Deane Dray |
RBC Capital |
127.25 $ |
153 $ |
25.75 % |
04/04/2024 |
| Nathan Jones |
Stifel Nicolaus |
99.8 $ |
133 $ |
33.20 % |
18/08/2023 |
| Richard Radbourne |
Atlantic Equities |
112.13 $ |
129 $ |
16.87 % |
16/11/2022 |
| Scott Graham |
Loop Capital Markets |
127.19 $ |
120 $ |
-7.19 % |
22/11/2021 |
| John Eade |
Argus Research |
129.82 $ |
150 $ |
20.18 % |
12/11/2021 |
| Andrew Kaplowitz |
Citigroup |
125.7 $ |
131 $ |
5.30 % |
04/08/2021 |
| Brian K. Lee |
Goldman Sachs |
116.2 $ |
107 $ |
-9.20 % |
05/05/2021 |